About CytaCoat

A unique, stable and universal antimicrobial coating for prevention of HAIs

Our story

CytaCoat AB is a private Swedish company located in the Karolinska Institutet Science Park AB in Solna (Stockholm area). The company was founded by a group of researchers from the Karolinska Institute, one of the foremost medical universities in the world, and the Royal Institute of Technology (KTH). It was a special purpose vehicle started with a goal to develop a new technology of antibacterial coating for medical devices. It was based on a discovery that our proprietary polymer surface exhibits a clear effect on several of the most problematic pathogenic bacteria that pose problems in healthcare today. Since then, the company has been focused on transforming this innovation into a fully viable commercial product and make it available through licenses.

CytaCoat has a fully equipped laboratory in the Karolinska Institutet Science Park, where both microbiology evaluation, optimisation of the CytaCoat technology and a pilot plant production can be performed. The company has also established contacts with clinical collaborators at Karolinska University Hospital Neonatal Unit and the Division of Clinical Microbiology. CytaCoat has also been cooperating with experienced consultants in regulatory, clinical research organisations, patent experts and providers of specialist analyses.

Board of directors

Per Wirsén


Find out more

Per is responsible for sales & partnerships and has a wealth of experience spanning 15 years in business development as co-founder and managing director of Wirsen and Males. In this capacity, he has worked as a business analyst and project manager for numerous companies

Birgitta Agerberth

Board member & Co Founder

Find out more

Birgitta is a Professor of Medical Microbial Pathogenesis at Karolinska Institutet, also an inventor of the CytaCoat technology and is a member of the CytaCoat board. She has extensive experience in the academic (at present 116 publications in scientific journals) and industry sectors. In addition to CytaCoat, she is also one of the founders of Akthelia Pharmaceutical, an Icelandic company developing substances which prevent and cure microbial infections

Jacob Odeberg

CEO & Co Founder

Find out more

Jacob obtained his PhD in 1998 in the area of gene expression technology. In parallel to finishing his medical studies, he built up a research group at the Department of Biotechnology (Karolinska) focusing on the role of common genetic variation in gene regulation and disease susceptibility. He joined the Cardiovascular Genetics and Genomics group, Karolinska Institutet in 2002, to which he remains associated today. He became Associate professor in Molecular Biotechnology in 2006. In 2013 he was appointed as Professor combined with a position as Consultant in Hematology and Internal Medicine at the Coagulation unit, Karolinska University Hospital Solna.

Nils Revvik

Board member

Find out more


Fredrik Palm

Board member

Find out more

Fredrik Palm acts as partnership and commercial advisor.  He has more than 20 years of experience within international life science business, mainly in sales and marketing positions at medical device companies, focusing on international expansion. His experience covers international management within sales, marketing and business development as well as concepts for value based communication. Palm has complemented his engineer background with studies in executive business management and strategic marketing.

Roger Granberg

Board member

Find out more


Markus Fagerlund

Board member

Find out more

Markus Fagerlund acts as partnership and commercial advisor. He has more than 25 years of experience from sales & marketing positions in companies like Xerox, Datscha and Newsec and many years as a leader. He is entrepreneurial with long experience in building up new business areas. Fagerlund has an international education in Marketing & Communication.


Anders Wirsén

R&D supervisor & Co Founder

Find out more

Anders is one of the inventors of the technology, he is supervising R&D in surface design and processing. Anders has a long experience in biomaterial developments and applications from

academic and industrial R&D including antithrombogenic and antimicrobial surfaces. He is an author and co-author of 35 publications in scientific journals and technical reports. He has been responsible for R&D and technical developments of the CytaCoat technology.

Åke Norberg

R&D Medical Biochemistry

Find out more

Åke is a chemist with more than 30 years of experience in research and development. Åke has a B.Sc. degree in Chemistry (organic chemistry), and PhD in Medical biochemistry

Jan Tejbrant

R&D Medicinal Chemist

Find out more

A chemist with more than 20 years of experience in research and development, combinatorial chemistry, synthesis and product development within demanding and fast-paced organisations. He was awarded Swedish Chemist of the Year 2000 by Pharmacia & Upjohn.

Contact us

13 + 15 =

CytaCoat ABRetzius väg 8 (House B3 Plan 3), 17165 Solna, SWEDEN Phone +46 8524 89900 | E-mail info@cytacoat.se

Design LIVE Reklambyrå